Oct 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Kezar Life Sciences were informed that the IND application for zetomipzomib, intended for lupus nephritis (LN) treatment, has been put on clinical hold.

Eton Pharmaceuticals revealed that it has engaged in an asset purchase deal to obtain Increlex® (mecasermin injection) from Ipsen S.A.

Theriva™ Biologics Reports Favorable Results in Phase 1b/2a Trial of SYN-004 (ribaxamase) for Allogeneic Hematopoietic Cell Transplant Patients.

ABL Bio, revealed that it has formed a clinical trial collaboration and supply agreement with MSD.

Alentis Therapeutics gains FDA IND approval for ALE.P02, an innovative CLDN1-ADC targeting the treatment of squamous cell cancers.

The FDA has authorized the use of Opdivo® (nivolumab) with chemotherapy before surgery and as a post-surgery treatment for resectable NSCLC.

This partnership will investigate the combined use of casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, and volrustomig.

The SC formulations of TALVEY® (talquetamab) and DARZALEX® (daratumumab) exhibit significant and lasting effects in relapsed or refractory multiple myeloma patients.

Dupixent is the pioneering biologic drug sanctioned in the United States for the treatment of these patients.

The FDA has given the green light to Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a unique muscarinic agonist for adult schizophrenia treatment.

AbbVie Reveals Promising Phase 3 TEMPO-1 Trial Results for Tavapadon as a Solo Parkinson’s Therapy.